iECURE
Private Company
Total funding raised: $115M
Overview
iECURE is a private, pre-revenue biotech leveraging a disruptive in vivo gene insertion platform to develop potentially curative treatments for rare liver disorders. The company's core strategy is built on an exclusive, foundational collaboration with the University of Pennsylvania's Gene Therapy Program (GTP), providing deep translational R&D expertise. Its most advanced asset, ECUR-506 for OTC deficiency, has received FDA RMAT designation and is in clinical trials, positioning iECURE as a notable player in next-generation gene editing.
Technology Platform
Mutation-agnostic in vivo gene insertion platform using gene editing to knock healthy copies of disease-causing genes into patient chromosomes for long-term, stable expression, initially focused on liver disorders.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
iECURE competes in the rapidly evolving gene editing and gene therapy space for liver diseases. Competitors include companies developing AAV-based gene replacement therapies, RNA-targeting approaches, and other gene editing platforms (e.g., CRISPR/Cas9, base editing). Its key differentiator is the exclusive partnership with Penn's GTP and its focus on precise gene insertion rather than gene addition or correction.